您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (9): 71-79.doi: 10.6040/j.issn.1671-7554.0.2015.514

• 临床医学 • 上一篇    下一篇

中国人群中血清TK1对不同恶性肿瘤诊断价值的Meta分析

刘京生1, 刘桂华1, 杜昆1, 赵倩2, 翁韶波1, 赵学英1, 张喜庄1, 金讯波3   

  1. 1. 华北石油管理局总医院泌尿外科, 河北 任丘 062552;
    2. 华北石油管理局总医院药材科, 河北 任丘 062552;
    3. 山东大学附属省立医院泌尿微创中心, 山东 济南 250021
  • 收稿日期:2015-05-25 出版日期:2015-09-10 发布日期:2015-09-10
  • 通讯作者: 金讯波。E-mail:16365451@qq.com E-mail:16365451@qq.com
  • 基金资助:
    河北省卫生厅青年科技课题(20110653)

Serum TK1 for the diagnosis of cancer in Chinese patients: a Meta-analysis

LIU Jingsheng1, LIU Guihua1, DU Kun1, ZHAO Qian2, WENG Shaobo1, ZHAO Xueying1, ZHANG Xizhuang1, JIN Xunbo3   

  1. 1. Department of Urology, North China Petroleum Administration Bureau General Hospital, Renqiu 062552, Hebei, China;
    2. Department of Pharmacy, North China Petroleum Administration Bureau General Hospital, Renqiu 062552, Hebei, China;
    3. Department of Minimally Invasive Urology Center, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2015-05-25 Online:2015-09-10 Published:2015-09-10
  • Contact: 金讯波。E-mail:16365451@qq.com E-mail:16365451@qq.com

PDF (PC)

764

摘要： 目的 系统评价核酸合成的关键酶——胸苷激酶1 (TK1) 在中国人群恶性肿瘤中的诊断价值。方法 在中国期刊全文数据库(CNKI)和万方数据库中检索2008年1月至2015年3月发表的相关临床研究,采用Revman 5.2和Meta Disc 1.4进行分析。结果 共检索到相关文献415篇,最终纳入45篇,包括2 976例肿瘤患者,并全部经“金标准”确诊。Meta分析结果显示,各亚组间均存在明显的异质性,血清TK1检测在中国人群不同类型恶性肿瘤中表现出中度敏感性,其中肺癌、乳腺癌、妇科恶性肿瘤、前列腺癌、胃癌、结直肠癌、食管癌亚组的合并诊断敏感性分别为0.508、0.638、0.524、0.656、0.583、0.546、0.681;相应诊断特异性分别为0.973、0.932、0.940、0.925、0.941、0.947、0.967。结论 血清TK1检测在中国人群不同类型恶性肿瘤的筛选及早期诊断中具有一定的临床应用价值,但尚不能单独作为肿瘤筛选和辅助的诊断标准。国内评估血清TK1诊断价值的诊断性试验质量不高,存在较大的异质性,需要更多高质量的研究进一步验证。

关键词: 敏感性, 胸苷激酶1, 癌症, Meta分析, 特异性

Abstract: Objective To evaluate significance of thymidine kinase 1 (TK1) detection in the diagnosis of malignant tumors in Chinese patients. Methods Clinical trials on TK1 detection published during Jan. 2008 to Mar 2015 were searched in databases of CNKI and Wan Fang. Revman 5.2 and Meta Disc 1.4 were used to perform the Meta-analysis.Results A total of 415 relevant articles were retrieved and 45 trials with 2,976 cancer patients (all diagnosed by the gold standard) were involved. Meta-analyses showed that the heterogeneity among studies was high, and the pooled Results suggested a moderate diagnostic efficacy. The sensitivities for lung cancer, breast cancer, gynecological cancer, prostatic cancer, gastric cancer, intestinal cancer and esophagus cancer were 0.508, 0.638, 0.524, 0.656, 0.583, 0.546, and 0.681, respectively. The specificities were 0.973, 0.932, 0.940, 0.925, 0.941, 0.947, and 0.967. Conclusion TK1 detection may have certain value in the early diagnosis and screening of malignant cancers, but it can not be serveed as an independent reference test. More high quality trials are required to confirm the significance of TK1 detection.

Key words: Thymidine kinase 1, Cancer, Specificity, Meta-analysis, Sensitivity

中图分类号: 

  • R730.4
[1] Aufderklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring[J]. Cancer Letters, 2012, 316(1):6-10.
[2] Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage[J]. J Biol Chem, 2010, 285(35):27327-27335.
[3] Xu Y, Shi QL, Ma H, et al. High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma[J]. Tumour Biol, 2012, 33(2):475-483.
[4] Stalhandske P, Wang L, Westberg S, et al. Homogeneous assay for realtime and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities[J]. Anal Biochem, 2013, 432(2):155-164.
[5] Xiang Y, Zeng H, Liu X, et al. Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis[J]. Biomed Rep, 2013, 1(4):629-637.
[6] 刘鹏飞, 姬舒荣.血清胸苷激酶1在恶性肿瘤筛查和复发转移监测中研究进展[J].中华临床医师杂志:电子版, 2013, 7(23):10858-10860. LIU Pengfei, JI Shurong. Progress advances on serum thymidine kinase 1 in screening and monitoring of malignant tumor recurrence and metastasis[J/CD]. Chin J Clinicians (Electronic Edition), 2013, 7(23):10858-10860.
[7] Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage[J]. J Biol Chem, 2010, 285(35):27327-27335.
[8] Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use[J]. Mol Clin Oncol, 2013, 1(1):18-28.
[9] Nisman B, Allweis T, Kaduri L, et al. Serum thymidine kinase 1 activity in breast cancer[J]. Cancer Biomark, 2010, 7(2):65-72.
[10] He E, Xu XH, Guan H, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma[J]. Nucleosides Nucleotides Nucleic Acids, 2010, 29(4-6):352-358.
[11] Wu BJ, Li WP, Qian C, et al. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma[J]. Tumour Biol, 2013, 34(2):643-648.
[12] 邹雄. 胸苷激酶1是恶性肿瘤预后判断的动态标志[J]. 实用检验医师杂志, 2013, 5(2):67-71. ZOU Xiong. Serum thymidine kinase 1 activity is a dynamic marker of the prognosis of malignant tumor[J]. Chinese Journal of Laboratory Pathologist, 2013, 5(2):67-71.
[13] 郭丽香, 刘树业. 胸苷激酶1—新型的细胞增殖动力学标志[J].哈尔滨医药, 2014(5):316-317. GUO Liuxiang, LIU Shuye. Thymidine kinase 1-a new cell proliferation marker[J]. Harbin Medical Journal, 2014(5):316-317.
[14] 徐文静, 刘德干. 血清胸苷激酶1与肿瘤[J]. 国际肿瘤学杂志, 2013, 40(9):643-645. XU Wenjing, LIU Degan. Serum thymidine kinase 1 and cancer[J]. Journal of International Oncology, 2013, 40(9):643-645.
[15] Chen G, He C, Li L, et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix[J]. BMC Cancer, 2013, 13:249. doi: 10.1186/1471-2407-13-249.
[16] Chen Y, YingM, Chen Y, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings[J]. Int J Clin Oncol, 2010, 15(4):359-368.
[17] Xu Y, Liu B, Shi QL, et al. Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung[J]. Int J Clin Exp Med, 2014, 7(8):2120-2128.
[18] Chen ZH, Huang SQ, Wang Y, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumors-A health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay[J]. Sensors, 2011, 11(12):11064-11080.
[19] Bolayirli M, Papila C, Korkmaz GG, et al. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy[J]. J Clin Lab Anal, 2013, 27(3):220-226.
[20] Chen F, Tang L, Xia T, et al. Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer[J]. Mol Clin Oncol, 2013, 1(5):894-902.
[21] Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer[J]. Exp Ther Med, 2012, 3(2):331-335.
[1] 李晶,鞠苇杭,刘珂. 泛癌细胞类型特异性基因共表达模式[J]. 山东大学学报 (医学版), 2025, 63(9): 31-39.
[2] 张润泽,薛付忠,杨帆. 基于多模态解耦对比学习的癌症亚型聚类方法[J]. 山东大学学报 (医学版), 2025, 63(8): 51-60.
[3] 温学龙,刘安慧,陈经纬,吴梦婷,杨岷. 急性非ST抬高型心肌梗死行冠状动脉旁路移植手术时机Meta分析[J]. 山东大学学报 (医学版), 2025, 63(5): 60-70.
[4] 王梦园,张春艳,于文文,寇琳娜,王世富. 2018—2021年山东省儿童与成人临床分离真菌的构成与主要菌种的体外抗真菌药物敏感性监测[J]. 山东大学学报 (医学版), 2025, 63(4): 83-93.
[5] 龚蓉,崔乃雪,陈恺悦,赵佳,单瑞洁,张训琪. 体感游戏在儿童癌症幸存者中的应用[J]. 山东大学学报 (医学版), 2025, 63(4): 94-99.
[6] 刘向荣,张新胜,杨荩冉,杨雪艳,刘钊,刘英华. ω-6/ω-3多不饱和脂肪酸比值对不同肿瘤发病风险的系统综述和Meta分析[J]. 山东大学学报 (医学版), 2024, 62(8): 34-48.
[7] 曹华琳,贾彦召,曲莉,尹昕. CircFAT1调节miR-296-3p/MAPRE1轴对鼻咽癌细胞增殖、凋亡和放疗敏感性的影响[J]. 山东大学学报 (医学版), 2023, 61(9): 38-46.
[8] 任慧欣,郑茂金,韩文灿,王超群,周云,裴冬生. 过氧化氢通过调控自噬增强宫颈癌的放疗敏感性[J]. 山东大学学报 (医学版), 2023, 61(6): 22-28.
[9] 焦光丽,石子馨,陈蓉,宋亚博,杨飞,崔书君. 基于增强CT影像组学预测卵巢癌患者铂类药物敏感性[J]. 山东大学学报 (医学版), 2023, 61(12): 62-69.
[10] 吴文静,孙媛,王光裕,吕晓晴,焉传祝,林鹏飞. 1例女性杜氏肌营养不良的分子遗传学机制[J]. 山东大学学报 (医学版), 2023, 61(10): 95-100.
[11] 吴瑞芳,李长忠. 女性生育力保护的现状与进展[J]. 山东大学学报 (医学版), 2022, 60(9): 1-7.
[12] 吴新莹,冯一平,常开锋,贾贤杰,薛付忠. 绿色覆盖与癌症发病的因果关联分析[J]. 山东大学学报 (医学版), 2022, 60(8): 115-119.
[13] 秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[14] 侯茹男,邵頔,秦廷廷,尚美美,申玉珍,孙晓杰. 山东省癌症患者烟草使用情况及影响因素分析[J]. 山东大学学报 (医学版), 2022, 60(6): 102-106.
[15] 陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发